RSLV-132
- Generic Name
- RSLV-132
A Study of RSLV-132 in Females With Sjögren's Syndrome
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Resolve Therapeutics
- Target Recruit Count
- 106
- Registration Number
- NCT06440525
- Locations
- 🇺🇸
Accurate Clinical Research, Richmond, Texas, United States
🇺🇸Resolve Clinical Site, San Antonio, Texas, United States
🇺🇸Evolution Research Center, Hialeah, Florida, United States
Phase 2 Study of RSLV-132 in Subjects With Long COVID
Phase 2
Completed
- Conditions
- Post-acute Corona Virus 19 (COVID-19) (Long COVID)
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Resolve Therapeutics
- Target Recruit Count
- 112
- Registration Number
- NCT04944121
- Locations
- 🇺🇸
Resolve Clinical Center, Seattle, Washington, United States
A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Resolve Therapeutics
- Target Recruit Count
- 28
- Registration Number
- NCT03247686
- Locations
- 🇬🇧
University Hospitals Birmingham, Birmingham, Edgbaston, United Kingdom
🇬🇧Newcastle upon Tyne Hospitals, Newcastle upon Tyne, Gosforth, United Kingdom
A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Resolve Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT02660944
- Locations
- 🇺🇸
Feinstein Institute for Medical Research, Manhasset, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Temple University, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath